North East and North Cumbria
ICS Formulary
1 Gastro-intestinal system
01-09-01 Other prepatations for biliary disorders
Elafibranor
Iqirvo
®
Formulary
80 mg film-coated tablets
Approved as an option for treating primary biliary cholangitis in adults in line with NICE
NICE TA1016: Elafibranor for previously treated primary biliary cholangitis
Obeticholic acid
Formulary
5mg & 10mg tablets
Approved for the treatment of primary biliary cholangitis in line with NICE and NHS England Commissioning Policy.
MHRA Drug Safety Update (April 2018): Obeticholic acid (Ocaliva▼): risk of serious liver injury in patients with pre-existing moderate or severe hepatic impairment; reminder to adjust dosing according to liver function monitoring
NICE TA443 Obeticholic acid for treating primary biliary cholangitis
Odevixibat
Bylvay
®
Formulary
Approved for the treatment of progressive familial intrahepatic cholestasis in line with NICE
NICE HST17: Odevixibat for treating progressive familial intrahepatic cholestasis
Links
Guidelines for the Management of Adults with Asymptomatic Liver Blood Test Abnormalities
MHRA Drug Safety Update (April 2018): Obeticholic acid (Ocaliva▼): risk of serious liver injury in patients with pre-existing moderate or severe hepatic impairment; reminder to adjust dosing according to liver function monitoring
NICE HST17: Odevixibat for treating progressive familial intrahepatic cholestasis
NICE TA1016: Elafibranor for previously treated primary biliary cholangitis
NICE TA443 Obeticholic acid for treating primary biliary cholangitis
NTAG: Transanal irrigation (TAI) systems (Peristeen Plus®, Aquaflush®, and QuFora®) for neurogenic bowel dysfunction, chronic constipation and chronic faecal incontinence
Key
Full Site